Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$178.58 USD

178.58
588,051

+2.21 (1.25%)

Updated Aug 4, 2025 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Zacks Equity Research

Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) second-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Zacks Equity Research

Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Becton Dickinson (BDX) Surges 5.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Becton Dickinson (BDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

BD (BDX) Receives FDA Nod to Address Critical Infusion Needs

by Zacks Equity Research

The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.

Zacks Equity Research

Reasons to Add HealthEquity (HQY) Stock to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Zacks Equity Research

Avantor's (AVTR) New Expansion Plans to Boost Workflow

by Zacks Equity Research

Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.

Zacks Equity Research

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

by Zacks Equity Research

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.

Zacks Equity Research

Here's Why You Should Add BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Zacks Equity Research

Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales

by Zacks Equity Research

Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.

Mark Vickery headshot

Top Analyst Reports for Walmart, AbbVie & Nike

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE).

Zacks Equity Research

Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.

Zacks Equity Research

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Zacks Equity Research

Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales

by Zacks Equity Research

Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.

Zacks Equity Research

BDX or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

STERIS (STE) Buys Surgical Instrumentation Platform From BDX

by Zacks Equity Research

STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.

Zacks Equity Research

BD's (BDX) Latest Product to Automate Clinical Flow Cytometry

by Zacks Equity Research

The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.

Zacks Equity Research

The Zacks Analyst Blog Highlights Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson

by Zacks Equity Research

Apple, UnitedHealth, Eli Lilly, Walmart and Becton, Dickinson are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, UnitedHealth & Eli Lilly

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

Zacks Equity Research

BD's (BDX) Latest Product Launch to Boost Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.

Zacks Equity Research

BD's (BDX) New FDA Approval to Improve MRSA Diagnostics

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.

Zacks Equity Research

BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.

Zacks Equity Research

Becton Dickinson (BDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?